Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference

Data from the ENMD-2076 Phase 1 Leukemia Trial to be Included

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ: ENMD) , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.
 

  (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

  --  Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m.
      Abstract No.: A106, "A Phase 1 study of ENMD-2076 in patients with
      relapsed or refractory acute myeloid leukemia (AML)," Halls C-D, 2nd
      floor.
  --  Poster Session: Monday, November 16, 2009 - 12:30 p.m. - 2:30 p.m.
      Abstract No.: A156, "Mechanisms of resistance to Aurora kinase B
      inhibitors in leukemia: development and characterization of in vitro
      models," Halls C-D, 2nd floor.

  --  Poster Session:  Wednesday, November 18, 2009 - 12:30 p.m. - 2:30 p.m.
      Abstract No: C75, "A novel multi-targeted Aurora A and VEGFR2 kinase
      inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and
      proapoptotic effects in combination with chemotherapy and trastuzumab
      in breast cancer cell lines," Halls C-D, 2nd floor.

  About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.
 

About EntreMed
 

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem® in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
 

Forward Looking Statements
 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid®, risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
 

  CONTACT:
  Ginny Dunn
  Associate Director, Corporate Communications & Investor Relations
  EntreMed, Inc.
  240.864.2643

Source: EntreMed

CONTACT: Ginny Dunn, Associate Director, Corporate Communications &
Investor Relations of EntreMed, Inc., +1-240-864-2643
 

Web Site: http://www.entremed.com/
http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
 

Posted: November 2009

View comments

Hide
(web3)